News & Events

AC Immune and Life Molecular Imaging Announce FDA Fast Track Designation for Tau PET Tracer

Swiss biopharmaceutical company AC Immune announced in late August that its partner, German biopharmaceutical company Life Molecular Imaging (LMI), received a Fast Track Designation from the US Food and Drug…

MORE

Emma Heming Willis Shares Her FTD Experience and Advocacy Work in “Town & Country” Magazine

Emma Heming Willis spoke with journalist Katie Couric about her journey as an FTD care partner, as well as her advocacy for FTD legislation and research following the diagnosis of…

MORE

Advancing Hope: AFTD Attends Tau Consortium Investigators Meeting

Members of the AFTD staff, along with several funding partner organizations, gathered with the world’s top scientists studying tauopathies for the 2024 Tau Consortium Investigators Meeting (TCIM) this September in…

MORE

Tips and Advice: Understanding Ambiguous Loss and Anticipatory Grief

Andy Atwood, a retired psychotherapist and clergyman, knows about grief. In addition to working as a grief counselor, he experienced grief firsthand after the 2021 death of his beloved younger…

MORE

Young Woman Tells Her Family’s FTD Story on Philadelphia News Segment

FTD care partner Hannah Clarke was interviewed on October 15 for a segment on Good Day Philadelphia about her experiences caring for her mother, Claudine, who is living with an…

MORE

Study Finds Suicidal Thoughts Likelier in People with Dementia, Calls for Better Supports

A study conducted by researchers at University College London (UCL) published in the journal Ageing Research Reviews finds that people diagnosed with dementia have a higher chance of experiencing suicidal…

MORE

AFTD Ambassador Shares Her Family’s FTD Story with Massachusetts Newspaper

Dawn O’Gara, an ATD Ambassador, spoke about her beloved father’s FTD diagnosis and how it spurred her activism in an article published in the Worcester Telegram & Gazette on October…

MORE

Astellas and AviadoBio Announce Exclusive License Agreement for FTD-GRN Gene Therapy

Astellas Pharma and AviadoBio have announced an exclusive license agreement for AVB-101, an experimental gene therapy for FTD-GRN currently undergoing a phase 1/2 clinical trial in the United States and…

MORE